March Outlook For Vertex Pharmaceuticals VRTX

After staging a rally from the start of 2019, Vertex (VRTX) has experienced some price setback as a result of a cut in the revenue forecasts from analysts, as pushback against pricing of its products in the UK and EU rage on. Here is the outlook for VRTX as we head towards the start of the second quarter of 2019.

VRTX recently got a downgrade and a cut in its target price by notable analysts as a result of some opposition to its treatments of cystic fibrosis in France and the UK. There has been some considerable pushback from patients in those locations, who are kicking against the prices of some the medication for cystic fibrosis from Vertex Pharmaceuticals, especially Orkambi.

Original source

Add comment

Please Sign in to be able to leave comments.